k Osimertinib anticancer drug Osimertinib anticancer drug. An oral osimertinib tablet labelled AZ80, sold under the trade name Tagrisso. Osimertinib is used in the treatment of nonsmall cell lung carcinoma NSCLC, and is a thirdgeneration epidermal growth factor receptor EGFR tyrosine kinase inhibitor. Patients taking this drug may develop resistance after approximately 10 months, and it can cause harm to the foetus so should be avoided by pregnant women. Osimertinib was approved for use by the EU in February 2016., by DR P. MARAZZISCIENCE PHOTO LIBRARY Stock Photo - Afloimages
Sign up
Login
All images
Osimertinib anti cancer drug Osimertinib anti cancer drug. An oral osimertinib tablet labelled AZ80, sold under the trade name Tagrisso. Osimertinib is used in the treatment of non small cell lung carcinoma  NSCLC , and is a third generation epidermal growth factor receptor  EGFR  tyrosine kinase inhibitor. Patients taking this drug may develop resistance after approximately 10 months, and it can cause harm to the foetus so should be avoided by pregnant women. Osimertinib was approved for use by the EU in February 2016., by DR P. MARAZZI SCIENCE PHOTO LIBRARY
RM

Osimertinib anti-cancer drug

Osimertinib anti-cancer drug. An oral osimertinib tablet labelled AZ80, sold under the trade name Tagrisso. Osimertinib is used in the treatment of non-small cell lung carcinoma (NSCLC), and is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Patients taking this drug may develop resistance after approximately 10 months, and it can cause harm to the foetus so should be avoided by pregnant women. Osimertinib was approved for use by the EU in February 2016., by DR P. MARAZZI/SCIENCE PHOTO LIBRARY

Details

ID
195005140

Collection

License type
Rights Managed

Photographer



Sign in
Member access
Login not found.